Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
about
Molecular testing in lung cancer in the era of precision medicineMulti-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analysesBevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysisBevacizumab: a review of its use in advanced cancer.
P2860
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Risk of hemoptysis in patients ...... ated with adjuvant bevacizumab
@ast
Risk of hemoptysis in patients ...... ated with adjuvant bevacizumab
@en
type
label
Risk of hemoptysis in patients ...... ated with adjuvant bevacizumab
@ast
Risk of hemoptysis in patients ...... ated with adjuvant bevacizumab
@en
prefLabel
Risk of hemoptysis in patients ...... ated with adjuvant bevacizumab
@ast
Risk of hemoptysis in patients ...... ated with adjuvant bevacizumab
@en
P2093
P2860
P50
P1476
Risk of hemoptysis in patients ...... ated with adjuvant bevacizumab
@en
P2093
Camelia S Sima
Christopher G Azzoli
David J Finley
Gregory J Riely
Katharine A R Price
Lee M Krug
Manjit S Bains
Matthew D Hellmann
Matthew G Fury
Michelle S Ginsberg
P2860
P2888
P304
P356
10.1007/S00280-013-2219-5
P577
2013-06-28T00:00:00Z